Atrasentan for hormone refractory prostate cancer
|
Status
|
Suspended
|
| Process |
STA pre-2018
|
| Referral date |
01 June 2004 |
|
Topic area
|
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
| 2nd appraisal committee meeting |
TBC |
Project Team
| Assessment Group / Evidence Review Group: |
TBC |
| Communications manager: |
TBC |
| Executive Lead: |
TBC |
| Project manager: |
TBC |
| Technical Lead: |
TBC |
|
Date
|
Update
|
|
27 May 2005
|
Topic summary published |
|
25 August 2006
|
This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme. |
|
8 January 2007
|
Topic is suspended as the manufacturer has not applied for EMEA regulatory approval at this time |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance